Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2011.084 | A randomized controlled study to evaluate the effect of n-3 polyunsaturated fatty acids on the progression of diabetic kidney disease | Dr Luk Andrea On Yan |
| 2011.418 | A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab (AMG 145) | Dr. LUK Andrea On Yan |
| 2013.071 | A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects With Severe Familial Hypercholesterolemia | Dr. LUK Andrea On Yan |
| 2013.070 | A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 | Dr. LUK Andrea On Yan |
| 2013.588 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE, THE VERTIS CV STUDY | Dr. LUK Andrea On Yan |
| 2017.271 | A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR–BLIND, SUBJECT-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE, TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO7062931 FOLLOWING SUBCUTANEOUSLY ADMINISTRATION IN HEALTHY CHINESE VOLUNTEERS |
Dr. LUK Andrea On Yan 陸安欣 |
| 2016.263 | Pharmacokinetics study of Trazodone Hydrochloride Prolonged-release tablets in Chinese Healthy Volunteers | Dr. LUK Andrea On Yan |
| 2014.426 | A STUDY TO EVALUATE THE EFFECT OF BTI320 (SUGARDOWN®) ON POST-PRANDIAL HYPERGLYCAEMIA IN HIGH RISK CHINESE SUBJECTS WITH PRE-DIABETES | Dr. LUK Andrea On Yan |
| 2017.451 | A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR-BLINDED, SUBJECT-BLINDED, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7020531 AND METABOLITES FOLLOWING ORAL ADMINISTRATION TO CHINESE HEALTHY VOLUNTEERS |
Dr. LUK Andrea On Yan 陸安欣 |
| 2016.046 | Interactive effects of testosterone, estradiol and CAG repeat polymorphism of androgen receptor gene on cardiovascular-renal diseases and mortality in men with type 2 diabetes |
Dr. LUK Andrea On Yan 陸安欣 |
| 2016.733 | Impact of heavy metal exposure during adolescence on glycemic status and cardio-metabolic risk factors in adulthood |
Dr. LUK Andrea On Yan 陸安欣 |
| 2014.056 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY WITH A 78-WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY | Dr. LUK Andrea On Yan |
| 2017.436 | Single - Dose, Randomized, Open-Label, Two-Way Crossover Study to Evaluate the Bioequivalence of Azilsartan Tablets in Chinese Healthy Volunteers |
Dr. LUK Andrea On Yan 陸安欣 |
| 2014.699 | Dose-response study of gevokizumab (S 78989 3mg, 10mg, 30mg or 60mg in patients with type 2 diabetes and diabetic kidney disease (DKD). A 66-week, international, multicenter, randomized, double-blind, parallel-group, placebo controlled, study. | Dr. LUK Andrea On Yan |
| 2015.634 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN ASIAN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY |
Dr. LUK Andrea On Yan 陸安欣 |
| 2017.298 | Incidence of diabetes and diabetes-related complications in Hong Kong | Dr. LUK Andrea On Yan |
| 2016.261 | Establishment of a registry on young-onset diabetes in Asia |
Dr. LUK Andrea On Yan 陸安欣 |
| 2017.248 | A different level of single-dose and multiple-dose study to evaluate the pharmacokinetics of ranolazine in a Chinese population |
Dr. LUK Andrea On Yan 陸安欣 |
| 2015.540 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease |
Prof. LUK Andrea On Yan 陸安欣 |
| 2016.264 | Single center, randomized, open labeled pharmacokinetics study of Azilsartan Tablets in Chinese healthy volunteers | Dr. LUK Andrea On Yan |
| 2016.297 | A Single-dose Pharmacokinetic/Pharmacodynamic, Safety and Tolerability Study of Subcutaneous Evolocumab Supplied by AML-14 Manufacture Site in Healthy Subjects of Chinese Descent |
Dr. LUK Andrea On Yan 陸安欣 |
| 2015.208 | Using C-peptide, anti-glutamic acid decarboxylase antibodies and body mass index to identify patients with young-onset type 2 diabetes for early insulin therapy | Dr. LUK Andrea On Yan |
| 2017.167 | Single-center, randomized, double-blind, placebo-controlled, single-dose and multiple-dose, parallel-group study to investigate pharmacokinetics, pharmacodynamics, safety and tolerability of vericiguat in Chinese healthy male subjects under fed condition |
Dr. LUK Andrea On Yan 陸安欣 |
| 2012.482 | Descriptive study of clinical profile of Hong Kong diabetic population | Dr Luk Andrea On Yan |
| 2014.441 | A MULTICENTRE RANDOMIZED PROGRAM BY USING A DIABETIC KIDNEY DISEASE (DKD) REGISTRY TO TREAT TO MULTIPLE TARGETS (TMT) (DKD-TMT) | Dr. LUK Andrea |
| 2015.487 | Retinopathy of Prematurity: Applicability and Compliance of Screening Guidelines in Hong Kong | Dr. LUK Abbie Sheung Wan |
| 2014.016 | Surgical Outcome of Medial Rectus Resection for Recurrent Exotropia | Dr. LUK Abbie |
| 2009.369 | Determinants and barriers for help seeking in persons with self-harm and aggressive ideations | Dr Lui Wing Cheong Victor |
| 2008.365 | Validation Study of Assessment of Capacity for Everday Decision-Making for Chinese Elderly | Dr Lui Wing Cheong |
| 2009.442 | Retrospective review of medical records to investigate the difference in the survival rate of out-of-hospital cardiac arrest patients before and after the implementation of 2005 Resuscitation Guildelines | Ms Lui Wai Yee Carrie |
| 2008.196 | Biological Implication of Elefated Serum Hepatocyte Growth Factor (HGF) in the Progressionof Nasopharyngeal Carcinoma (NPC) | Ph.D., Assistant Professor LUI Wai Yan Vivian |
| 2008.195 | High-Content Screening (HCS) Platform for Molecular Drug Testing, Therapeutic Target Identification and Mechanistic Signaling Studies in Asian Prevalent Cancers | Ph.D., Assistant Professor LUI Wai Yan Vivian |
| 2008.022 | Oncogenic Dependency on Receptor Tyrosine Kinase (RTK): Implication for Molecular Targeting in Nasopharyngeal Carcinoma (NPC) | Ph.D., Assistant Professor LUI Wai Yan Vivian |
| 2011.612 | Comparison of satisfaction with communication during general outpatient consultation of doctors and patients | Ms Lui Wai Yan |
| 2010.081 | Oncogenic Regulation of TIGAR by STAT3: A Mechanistic Study | Ph.D. LUI Vivian Wai Yan |
| 2017.293 | ALK/PIK3CA Genetic Coupling: Implications for Progression and Personalized Therapy in Head and Neck Cancer |
Dr. LUI Vivian Wai Yan 呂偉欣 |
| 2017.145 | RAC1 Genomic Alterations Drive Head and Neck Cancer Progression |
Dr. LUI Vivian Wai Yan 呂偉欣 |
| 2011.282 | EFFECTIVENESS OF TOE SPREADER & DYNAMIC HALLUX VALGUS STRAP ON FOOT FUNCTION FOR JUVENILE HALLUX VALGUS - PROSPECTIVE, CROSSOVER RANDOMIZED CONTROL TRIAL | Dr. Lui Tun Hing |
| 2025.139 | Epidemiology of fusariosis in NTEC | Dr. LUI Tin Long |
| 2009.282 | Socio-demographic Risk Factors for adolescent Sports Injury in Hong Kong: A Pilot Study | Ms Lui Tai Wah |
| 2022.323 | Effectiveness of the Current Use of Hospital Authority (HA) Mobile Application HA Go in Exercise Program for Knee Osteoarthritis (OA) in Local Elderly Patients |
Ms. LUI Sweetie R. 雷蕢珊 |
| 2023.490 | International Liver cAncer Database (ILIAD) Consortium Study | Dr. LUI Rashid N.S. |
| 2022.371 | Multicentre assessment of liver frailty using the Liver frailty index in patients with unresectable hepatocellular carcinoma (HCC) undergoing transarterial chemoembolisation (TACE) or systemic therapy | Dr. LUI Rashid N.S. |
| 2023.465 | Normal saline versus lactated Ringer’s solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: the WATERLAND trial | Dr. LUI Rashid N.S. |
| 2025.312 | The impact of contemporary neoadjuvant and adjuvant chemotherapy treatment regimens on recurrence and survival in resectable, borderline resectable, locally advanced and metastatic adenocarcinoma arising from IPMN and internal validation of 2023 KYOTO Guidelines: ADENO-IPMN 2 study | Dr. LUI Rashid N.S. |
| 2019.304 | Single Arm, Open-label Trial on the Efficacy of Pantoprazole, Amoxicillin and Clarithromycin Triple Therapy for 14 Days as First-line Therapy for Helicobacter pylori in Hong Kong and Outcomes of Targeted Screening for Household Members |
Dr. LUI Rashid N. 雷諾信 |
| 2019.507 | Helicobacter pylori, Atrophic Gastritis and Intestinal Metaplasia Registry | Dr. LUI Rashid |
| 2020.588 | Guangzhou-Oxford-Taipei-HongKong International Collaborative Sessile Serrated Lesion Study | Dr. LUI Rashid |
| 2021.145 | Multicenter prospective study of colorectal serrated lesions in the Asia-Pacific region | Dr. Lui Rashid |
| 2021.217 | coMpliAnce with evideNce-based cliniCal guidelines in the managemenT of acute biliaRy pancreAtitis (MANCTRA-1). | Dr Lui Rashid |
Page 102 of 265.